Autopsy report · NCT04787250

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

“Changes to protocol design”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Adaptive Phage Therapeutics, Inc.

Sponsor type

Industry

Conditions

Prosthetic Joint Infection

Interventions

Phage Therapy; Two-Stage Exchange Arthroplasty

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
  “Replaced by another protocol” (82% match in meaning)
• The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study
  “Protocol design under review.” (81% match in meaning)
• A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee
  “To be replaced by a different protocol” (81% match in meaning)
• Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
  “to be replaced with a different protocol” (80% match in meaning)
• RCT for Women With a Persisting Pregnancy of Unknown Location
  “A new protocol was written to replace this protocol.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.